FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2164658411> ?p ?o ?g. }

• W2164658411 endingPage "311" @default.
• W2164658411 startingPage "302" @default.
• W2164658411 abstract "Background. Electrochemotherapy provides good local tumor control but requires adjuvant treatment for increased local response and action on distant metastasis. In relation to this, intramuscular interleukin-12 (IL-12) gene electrotransfer, which provides systemic shedding of IL-12, was combined with local electrochemotherapy with cisplatin. Furthermore, the dependence on tumor immunogenicity and immunocompetence of the host on combined treatment response was evaluated. Materials and methods. Sensitivity of SA-1 sarcoma and TS/A carcinoma cells to electrochemotherapy with cisplatin was tested in vitro . In vivo, intratumoral electrochemotherapy with cisplatin (day 1) was combined with a single (day 0) or multiple (days 0, 2, 4) intramuscular murine IL-12 (mIL-12) gene electrotransfer. The antitumor effectiveness of combined treatment was evaluated on immunogenic murine SA-1 sarcoma in A/J mice and moderately immunogenic murine TS/A carcinoma, in immunocompetent BALB/c and immunodeficient SCID mice. Results. Electrochemotherapy in vitro resulted in a similar IC50 values for both sarcoma and carcinoma cell lines. However, in vivo electrochemotherapy was more effective in the treatment of sarcoma, the more immunogenic of the tumors, resulting in a higher log cell kill, longer specific tumor growth delay, and also 17% tumor cures compared to carcinoma where no tumor cures were observed. Adjuvant intramuscular mIL-12 gene electrotransfer increased the log cell kill in both tumor models, potentiating the specific tumor growth delay by a factor of 1.8-2 and increasing tumor cure rate by approximately 20%. In sarcoma tumors, the potentiation of the response by intramuscular mIL- 12 gene electrotransfer was dose-dependent and also resulted in a faster onset of tumor cures. Comparison of the carcinoma response to the combined treatment modality in immunocompetent and immunodeficient mice demonstrated that the immune system is needed both for increased cell kill and for attaining tumor cures. Conclusions. Based on the comparison of the antitumor effectiveness of electrochemotherapy to intratumoral cisplatin administration, we can conclude that the fraction of cells killed and the tumor cure rate are higher in immunogenic sarcoma tumor compared to moderately immunogenic carcinoma tumor. The tumor cell kill and cure rate depend on the immune response elicited by the destroyed tumor cells, which might depend on the tumor immunogenicity. The effect of adjuvant intramuscular mIL-12 gene electrotransfer is dependent on the amount of IL-12 in the system and the immune competence of the host, as demonstrated by the dose-dependent increase in the cure rate of SA-1 tumors after multiple intramuscular mIL-12 gene electrotransfer and in the differential cure rate of TS/A tumors growing in immunocompetent and immunodeficient mice." @default.
• W2164658411 created "2016-06-24" @default.
• W2164658411 creator A5010273003 @default.
• W2164658411 creator A5028438290 @default.
• W2164658411 creator A5031363850 @default.
• W2164658411 creator A5041997129 @default.
• W2164658411 creator A5049322851 @default.
• W2164658411 creator A5063064431 @default.
• W2164658411 creator A5070257255 @default.
• W2164658411 creator A5082272086 @default.
• W2164658411 creator A5086406281 @default.
• W2164658411 date "2012-10-01" @default.
• W2164658411 modified "2023-10-18" @default.
• W2164658411 title "Potentiation of electrochemotherapy by intramuscular IL-12 gene electrotransfer in murine sarcoma and carcinoma with different immunogenicity" @default.
• W2164658411 cites W1550649759 @default.
• W2164658411 cites W1559795923 @default.
• W2164658411 cites W1892229162 @default.
• W2164658411 cites W1968562981 @default.
• W2164658411 cites W1980569890 @default.
• W2164658411 cites W1990955233 @default.
• W2164658411 cites W2033743897 @default.
• W2164658411 cites W2036440806 @default.
• W2164658411 cites W2047538068 @default.
• W2164658411 cites W2061471966 @default.
• W2164658411 cites W2073431012 @default.
• W2164658411 cites W2088277708 @default.
• W2164658411 cites W2094187045 @default.
• W2164658411 cites W2122387392 @default.
• W2164658411 cites W2125985473 @default.
• W2164658411 cites W2130987112 @default.
• W2164658411 cites W2144688973 @default.
• W2164658411 cites W2175689371 @default.
• W2164658411 doi "https://doi.org/10.2478/v10019-012-0044-9" @default.
• W2164658411 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3572893" @default.
• W2164658411 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23412658" @default.
• W2164658411 hasPublicationYear "2012" @default.
• W2164658411 type Work @default.
• W2164658411 sameAs 2164658411 @default.
• W2164658411 citedByCount "51" @default.
• W2164658411 countsByYear W21646584112013 @default.
• W2164658411 countsByYear W21646584112014 @default.
• W2164658411 countsByYear W21646584112015 @default.
• W2164658411 countsByYear W21646584112016 @default.
• W2164658411 countsByYear W21646584112017 @default.
• W2164658411 countsByYear W21646584112018 @default.
• W2164658411 countsByYear W21646584112019 @default.
• W2164658411 countsByYear W21646584112020 @default.
• W2164658411 countsByYear W21646584112021 @default.
• W2164658411 countsByYear W21646584112022 @default.
• W2164658411 countsByYear W21646584112023 @default.
• W2164658411 crossrefType "journal-article" @default.
• W2164658411 hasAuthorship W2164658411A5010273003 @default.
• W2164658411 hasAuthorship W2164658411A5028438290 @default.
• W2164658411 hasAuthorship W2164658411A5031363850 @default.
• W2164658411 hasAuthorship W2164658411A5041997129 @default.
• W2164658411 hasAuthorship W2164658411A5049322851 @default.
• W2164658411 hasAuthorship W2164658411A5063064431 @default.
• W2164658411 hasAuthorship W2164658411A5070257255 @default.
• W2164658411 hasAuthorship W2164658411A5082272086 @default.
• W2164658411 hasAuthorship W2164658411A5086406281 @default.
• W2164658411 hasBestOaLocation W21646584111 @default.
• W2164658411 hasConcept C104317684 @default.
• W2164658411 hasConcept C111599444 @default.
• W2164658411 hasConcept C126322002 @default.
• W2164658411 hasConcept C142724271 @default.
• W2164658411 hasConcept C150903083 @default.
• W2164658411 hasConcept C159654299 @default.
• W2164658411 hasConcept C186852380 @default.
• W2164658411 hasConcept C203014093 @default.
• W2164658411 hasConcept C207001950 @default.
• W2164658411 hasConcept C2776232574 @default.
• W2164658411 hasConcept C2776694085 @default.
• W2164658411 hasConcept C2777108052 @default.
• W2164658411 hasConcept C2777701055 @default.
• W2164658411 hasConcept C2777863537 @default.
• W2164658411 hasConcept C2778239845 @default.
• W2164658411 hasConcept C2778256501 @default.
• W2164658411 hasConcept C2780868878 @default.
• W2164658411 hasConcept C502942594 @default.
• W2164658411 hasConcept C55493867 @default.
• W2164658411 hasConcept C71924100 @default.
• W2164658411 hasConcept C86803240 @default.
• W2164658411 hasConcept C8891405 @default.
• W2164658411 hasConceptScore W2164658411C104317684 @default.
• W2164658411 hasConceptScore W2164658411C111599444 @default.
• W2164658411 hasConceptScore W2164658411C126322002 @default.
• W2164658411 hasConceptScore W2164658411C142724271 @default.
• W2164658411 hasConceptScore W2164658411C150903083 @default.
• W2164658411 hasConceptScore W2164658411C159654299 @default.
• W2164658411 hasConceptScore W2164658411C186852380 @default.
• W2164658411 hasConceptScore W2164658411C203014093 @default.
• W2164658411 hasConceptScore W2164658411C207001950 @default.
• W2164658411 hasConceptScore W2164658411C2776232574 @default.
• W2164658411 hasConceptScore W2164658411C2776694085 @default.
• W2164658411 hasConceptScore W2164658411C2777108052 @default.
• W2164658411 hasConceptScore W2164658411C2777701055 @default.
• W2164658411 hasConceptScore W2164658411C2777863537 @default.
• W2164658411 hasConceptScore W2164658411C2778239845 @default.

• next